Serre-Beinier Véronique

Dr. Véronique Serre-Beinier

Head of Division / Biologist

022 379 51 07

 After graduated as a biochemical engineer from the National Institutes of Science and Technology (INSA) in Fran (Lyon) in 1991, I completed my PhD thesis in Biology at the CEA Grenoble and graduated from the Université Joseph Fourier of Grenoble in 1996. I pursued my research at Pharmacology and Toxicoloy Institute, laboratory of Prof. Bernard Thorens, in Lausanne, where I studied the role of the glucagon-like peptide-1 receptor in the beta-cell glucose competence. Then, I moved to the Faculty of Medicine at Geneva in 1998, working on the gap junction communication in beta cells in the laboratory of Prof. Paolo Meda. In 2003, I joined the Surgery Department of the University of Geneva, in the lab of Prof. Léo Buhler, Visceral Surgery Unit, studying the pancreatic islets vascularization. Since 2009, I was in charge of the basic research projects of the Thoracic and Endocrine Surgery Unit in Geneva, supervised by Prof. Frédéric Triponez. We established several pre-clinical human models (in vitro, ex vivo, in vivo) of mesothelioma and lung cancers. Currently, we are focusing on the translation of basic research to clinical application by means of ex vivo culture of human lung tumors to test anti-cancer drug efficacy, including immunotherapy. I am actively teaching for more than 20 years at Bachelor, Masters and post-graduate levels.

Our research focuses on two major axes, the role of the inflammation in the development of mesothelioma and lung cancers, and the establishment of pre-clinical tumor models. We provided strong evidence that chronic inflammation induced by asbestos led to a tumor-promoting environment activating MIF/CD74 signaling, YAP/TAZ signaling and RNA editing, prior to mesothelioma development. Macrophages and mesothelioma precursor cells (MPC) accumulated in the inflammatory environment, facilitating tumorigenesis, suggesting that MPC may function as mesothelioma stem cells (MSC). Mesothelioma-associated macrophages (MAM) shared some phenotypes with MPC/MSC and could play roles in mesothelioma development. We observed that the monocyte-derived macrophages, recruited in a CCR2-dependent manner, played a predominant role in the development of mesothelioma. In contrast, tissue-resident macrophages originating from embryonic sources, may be more efficient in activating the T cell response, having a protective effect. MAM derived from circulating monocytes could thus be an important target for immunotherapy in clinical trials, particularly in combination with immune checkpoint blockade.

We established several pre-clinical models (in vitro, in ovo, ex vivo and in vivo) of human mesothelioma and lung cancers to study, on one hand, the role of the inflammation on tumorigenesis, and on the other hand the functional and mechanistic effects of treatments. We plan to adapt our spheroid model in clinic to characterize the efficacy of anti-cancer drugs for patient diagnosed with lung cancer.



  • Gendre DAJ, Ameti E, Karenovics W, Perriraz-Mayer N, Triponez F, Serre-Beinier V. Optimization of tumor spheroid model in mesothelioma and lung cancers and anti-cancer drug testing in H2052/484 spheroids. Oncotarget 2021 Nov 23;12(24):2375-2387. doi: 10.18632/oncotarget.28134.
  • Colin DJ, Cottet-Dumoulin D, Faivre A, Germain S, Triponez F, Serre-Beinier V. Experimental Model of Human Malignant Mesothelioma in Athymic Mice. Int J Mol Sci. 2018, 26;19(7) - doi: 10.3390/ijms19071881
  • Rehrauer H, Wu L, Blum W, Pecze L, Henzi T, Serre-Beinier V, Aquino C, Vrugt B, de Perrot M, Schwaller B, Felley-Bosco E. How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations. Oncogene. 2018, 37(20):2645-2659- doi: 10.1038/s41388-018-0153-z
  • D'Amato-Brito C, Cipriano D, Colin DJ, Germain S, Seimbille Y, Robert JH, Triponez F, Serre-Beinier V. Role of MIF/CD74 signaling pathway in the development of pleural mesothelioma. Oncotarget 2016, 7(10):11512-25 - doi: 10.18632/oncotarget.7314
  • Otterström C, Soltermann A, Opitz I, Felley-Bosco E, Weder W, Stahel RA, Triponez F, Robert JH, Serre-Beinier V. CD74: a new prognostic factor for patients with malignant pleural mesothelioma. British Journal of Cancer 2014, 110(8):2040-2046 - doi: 10.1038/bjc.2014.117

Link to full publication list (e.g. Google Scholar): Here